SCHEDULE 13G/A: Systematic Financial Management LP Discloses 6.15% Stake in AngioDynamics Inc.

Systematic Financial Management LP has filed an amended Schedule 13G, reporting a beneficial ownership of 6.15% in AngioDynamics Inc. as of December 31, 2024.

Summary

• Systematic Financial Management LP, an investment adviser based in New Jersey, has filed an Amendment No. 1 to Schedule 13G.
• The filing reports beneficial ownership of shares in AngioDynamics Inc. (CUSIP: 03475V101).
• As of December 31, 2024, Systematic Financial Management LP beneficially owns an aggregate of 2,521,066 shares of AngioDynamics Inc.
• This aggregate amount represents 6.15% of the class of securities.
• The reporting person holds sole voting power over 1,484,876 shares and sole dispositive power over all 2,521,066 shares.
• There is no shared voting or shared dispositive power reported.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: A Schedule 13G filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment about the issuer's performance or prospects. It is a neutral regulatory report.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• Michele Egeberg, Managing Director, Compliance for Systematic Financial Management LP, certified that 'to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.'

Industry Context

This filing indicates a significant institutional investment in AngioDynamics Inc., a company operating in the medical device sector. Such disclosures are common for investment firms managing portfolios that include publicly traded companies.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an institutional investor can influence market perception and potentially provide a level of confidence or scrutiny regarding the company's stock.

Key Dates

Keywords

AngioDynamics Inc., Systematic Financial Management LP, Schedule 13G, Beneficial Ownership, Investment Adviser, Medical Devices, Healthcare, SEC Filing, Institutional Investor